In 2 months, the US market opens for Audientes hearing aids

Audientes lån

30 million Americans need a hearing aid. Many of these don’t have one because they can’t afford one, as subsidies are not generally provided in the US, as in Denmark, for example. This puts one of the key elements of Audientes’ investment case in place.

Audientes (AUDNTS – share price DKK 6.50) has developed a hearing aid for people with low to moderate hearing loss for the globally very large segment of people who want a high quality hearing aid but cannot afford one from the major manufacturers such as Demant, Sonova or GN Store Nord.

A big problem and a large market

The problem is big in 3rd world countries, including India, which is Audientes’ first focus market. But it’s also a problem in the US, where 30 million people have an unmet need for a hearing aid. That’s why the FDA has now – finally and with some resistance from the big, established manufacturers – opened up OTC sales of hearing aids to people with low to moderate hearing loss. OTC means that the hearing aids can be sold over the counter and do not require special fitting at a hearing clinic, but can be bought in, for example, ordinary shops and glasses stores. This is done to lower prices and increase innovation for this segment – in line with Audientes’ mission and vision.

Read more: Audientes changes direction

Sales in the US in 2023

The OTC market will open in mid-October, but Audientes will not then be ready to launch a product that meets the specific requirements of the FDA on, for example, maximum amplification and volume control, etc. However, Audientes expects to be able to launch its hearing aid in the US as early as next year.

25 August – Focus on sales

The investment case in Audientes is centered on the development of sales of the Ven hearing aid, which was launched in India this year. Information about the sale probably helped sow doubt among investors about how big the growth is, which combined with announcements about a stock exchange switch, the raising of a short-term loan and a capital raising in H2 2022 all contributed to a falling share price.

1-year price development of Audientes relative to Kapital Partner Nordic Health Care Index

Disclaimer

Selected cases

Would you like to receive one of our newsletters? Please fill the form below. (Newsletters are in danish)

  • Investment cases – Newsletters with current investment cases from the Nordic growth exchanges and the life science sector.
  • IPOs – Updates on new and ongoing IPOs in Scandinavia and their results. (Newsletter from Nyemission.dk)
  • Nyheder – News from and about Kapital Partner, including insight into the capital markets and stock exchange listings as well as invitations to investor meetings and events.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*If you want information about our upcoming investment association with a focus on the Nordic growth exchanges, including the opportunity to invest, sign up for the newsletter. Nyheder.




Investor network:

Do you want to be part of Kapital Partner’s investor network, where you get access to investments in companies and issues, as well as invitations to investor-oriented events,
please fill out the form in here.

Del indlægget på sociale media eller på email. 

LinkedIn
Facebook
Twitter
Email